These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2154922)

  • 1. Mitomycin is active against refractory germ-cell tumors. A phase II study.
    Hoskins P; Coppin CM; Murray N
    Am J Clin Oncol; 1990 Feb; 13(1):35-8. PubMed ID: 2154922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.
    Hoskins PJ; McMurtrie E; Swenerton KD
    Am J Clin Oncol; 1990 Oct; 13(5):416-9. PubMed ID: 2220661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H; Hoshi A
    Jpn J Clin Oncol; 1985 Mar; 15(1):61-5. PubMed ID: 3981815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
    Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
    Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.
    Broun ER; Nichols CR; Kneebone P; Williams SD; Loehrer PJ; Einhorn LH; Tricot GJ
    Ann Intern Med; 1992 Jul; 117(2):124-8. PubMed ID: 1318648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin.
    Motzer RJ; Bosl GJ; Tauer K; Golbey R
    Cancer Treat Rep; 1987 Feb; 71(2):197-8. PubMed ID: 3026627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of recurrent cervical cancer with cis-platinum and mitomycin C: a phase II study.
    Malviya VK; Deppe G; Schoenmaker M
    Am J Clin Oncol; 1989 Oct; 12(5):438-41. PubMed ID: 2508464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II evaluation of weekly mitomycin-C (NSC-26980) for patients with metastatic GI and breast malignancies.
    Hum GJ; Bogdon DL; Bateman JR
    Oncology; 1974; 30(3):236-43. PubMed ID: 4459738
    [No Abstract]   [Full Text] [Related]  

  • 10. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
    Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer.
    Creech RH; Catalano RB; Shah MK; Dayal H
    Cancer; 1983 Mar; 51(6):1034-40. PubMed ID: 6821868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitomycin C therapy in superficial bladder cancer.
    Denis L; Keuppens F; Hendrickx G
    Prog Clin Biol Res; 1985; 185B():113-22. PubMed ID: 3929269
    [No Abstract]   [Full Text] [Related]  

  • 13. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
    Hayashi Y; Kato M; Matsuura T; Yamada Y; Adachi S; Ito G; Yamamoto K; Takeuchi T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1455-60. PubMed ID: 2167632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
    Mobley WC; Loening SA; Narayana AS; Culp DA
    Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
    Srougi M; Simon SD; de Góes GM
    J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.
    Alberts DS; Kronmal R; Baker LH; Stock-Novack DL; Surwit EA; Boutselis JG; Hannigan EV
    J Clin Oncol; 1987 Nov; 5(11):1791-5. PubMed ID: 2445932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of everolimus in refractory testicular germ cell tumors.
    Mego M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rajec J; Sycova-Mila Z; Chovanec M; Rejlekova K; Zuzák P; Ondrus D; Spanik S; Reckova M; Mardiak J
    Urol Oncol; 2016 Mar; 34(3):122.e17-22. PubMed ID: 26612480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
    Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
    Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy.
    Lopez M; Papaldo P; Di Lauro L; Barduagni M; Perno CF; Barduagni A
    Oncology; 1983; 40(4):244-7. PubMed ID: 6408547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
    Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
    Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.